Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database

INTRODUCTION: Non-small cell lung cancer (NSCLC) is often caused by molecular alterations that can be detected by predictive biomarkers including mutations or amplifications of several genes. Several tyrosine kinase inhibitors (TKIs) have been approved in Europe by the European Medicines Agency (EMA...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbieri, Maria Antonietta, Sorbara, Emanuela Elisa, Cicala, Giuseppe, Santoro, Vincenza, Cutroneo, Paola Maria, Franchina, Tindara, Santarpia, Mariacarmela, Silvestris, Nicola, Spina, Edoardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727240/
https://www.ncbi.nlm.nih.gov/pubmed/36505840
http://dx.doi.org/10.3389/fonc.2022.1005626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727240/
https://www.ncbi.nlm.nih.gov/pubmed/36505840
http://dx.doi.org/10.3389/fonc.2022.1005626

Ejemplares similares